Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.44 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27713684 | 0.83 | PTK2 (0.45) | TTBK1TTBK2PAK4CYP2C9CYP2C19 | |
| SCHEMBL11936703 | 0.81 | CYP2C9 (0.44) | CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL1716213 | 0.81 | TERT (0.38) | TTBK1TTBK2PAK4CYP2C9CYP2C19 | |
| SCHEMBL1716090 | 0.81 | KCNH2 (0.57) | TTBK1TTBK2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL16206661 | 0.80 | CYP2C9 (0.52) | CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL10267879 | 0.79 | CYP2C9 (0.41) | CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL10251137 | 0.78 | BCDIN3D (0.42) | CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL12094484 | 0.78 | CYP2C9 (0.40) | CYP2C9CYP2C19CYP1A2CYP2D6PTK2 | |
| SCHEMBL11936691 | 0.78 | CYP2C9 (0.46) | TTBK1TTBK2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL13996746 | 0.77 | CYP2C9 (0.58) | CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354532-B2 | Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354532-B2 | Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354532-B2 | Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| EP-1877411-B9 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-1877411-B9 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8227601-B2 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227601-B2 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227601-B2 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-1877411-B1 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-1877411-B1 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | INTRABIOTICS PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | INTRABIOTICS PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | INTRABIOTICS PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| EP-1877411-A4 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1877411-A2 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | Ardea Biosciences, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006122003-A2 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | TYMP, TPMT, PNP | TTBK1 4040/4885TTBK2 4070/4885PAK4 1423/4885 |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | PNP, TPMT, DUT | TTBK1 4306/4885TTBK2 4602/4885PAK4 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.